A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer

Carlos Gomez-Martin,J. C. Camara,H. Cortes,C. Jara,Cristina Grávalos,B. Rubio,Maria L. Amador,Manuel Hidalgo

A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer

2016

Carlos Gomez-Martin
J. C. Camara
H. Cortes
C. Jara
Cristina Grávalos
B. Rubio
Maria L. Amador
Manuel Hidalgo

4611 Background: Erlotinib is an EGFR TKI active in combination with gemcitabine in p with advanced pancreatic cancer (PC). The combination of gemcitabine and bevacizumab is also active in PC. A ph...

Keywords:

Gemcitabine
Bevacizumab
Pathology
Pancreatic cancer
Erlotinib
Oncology
Internal medicine
Medicine
in patient
egfr tki
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations